QbD Enabled Development and Evaluation of Pazopanib Loaded Nanoliposomes for PDAC Treatment

• Published in: AAPS PharmSciTech Vol. 25; no. 5; p. 97
• Main Authors: Shinde, Aishwarya, Panchal, Kanan, Patra, Parameswar, Singh, Sonali, Enakolla, Sucharitha, Paliwal, Rishi, Chaurasiya, Akash
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 06.05.2024
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Biochemistry; Biomedical and Life Sciences; Biomedicine; Biotechnology; Carcinoma, Pancreatic Ductal - drug therapy; Cell Line, Tumor; Cell Survival - drug effects; Chemistry, Pharmaceutical - methods; Drug Liberation; Humans; Indazoles - administration & dosage; Indazoles - pharmacology; Liposomes; Nanoparticles - chemistry; Pancreatic Neoplasms - drug therapy; Particle Size; Pharmacology/Toxicology; Pharmacy; Polyethylene Glycols - chemistry; Pyrimidines - administration & dosage; Pyrimidines - chemistry; Pyrimidines - pharmacokinetics; Pyrimidines - pharmacology; Research Article; Sulfonamides - administration & dosage; Sulfonamides - chemistry; Sulfonamides - pharmacology; PDAC; Liposomes; Quality-by-Design; VEGF Inhibitor; Pazopanib

Pancreatic ductal adenocarcinoma (PDAC) is one of the highly fatal types of cancer with high mortality/incidence. Considering the crucial role of vascular endothelial growth factor (VEGF) in PDAC progression, its inhibition can be a viable strategy for the treatment. Pazopanib, a second-generation V...